Lupus kidney drug trial pulled before it began
NCT ID NCT04883619
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a planned phase 2 study testing nipocalimab, an experimental drug, in adults with active lupus nephritis (kidney inflammation caused by lupus). The trial aimed to see if adding nipocalimab to standard treatment could improve kidney function. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nipocalimab
- What this could lead to
- If it worked, nipocalimab could offer a new treatment option for lupus nephritis, potentially improving kidney outcomes when added to standard care.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data exist. Even if run, early-phase results often fail to confirm benefit, and risks like infection or infusion reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a single infusion tame tough lupus?
- Can a smartphone app bridge the lupus care gap for women of color?
- Can a single drug calm lupus kidney disease without a cocktail of meds?
- Cancer drug shows promise for lupus kidney disease